Low-dose Decitabine for the Treatment of Decreased Donor Chimerism After Allogeneic Stem Cell Transplantation
Status:
Completed
Trial end date:
2021-03-01
Target enrollment:
Participant gender:
Summary
Decreasing donor chimerism is considered as an early sign of graft failure or relapse in
patients undergoing allogeneic stem cell transplantation. The treatment option included
tapering or stop of immunosuppression and or donor lymphocyte infusion (DLI) which may
restore a full donor chimerism but subsequent graft versus host disease (GVHD) is the major
complications. In this single arm prospective study, the investigator evaluate the effect and
safety of low-dose decitabine alone or with DLI in patients with decreased donor chimerism
after allo-HSCT.